We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 47

Commission publishes fourth monitoring report on pharmaceutical patent settlements

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • February 11 2014

The European Commission has published its fourth Report on the Monitoring of Patent Settlements (the report), concerning pharmaceutical patent

CJEU Georgetown University SPC judgment

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • January 22 2014

Following hot on the heels of the 14 November 2013 opinion given by the Advocate General in Georgetown University C-48412, the Court of Justice of

CJEU actavis and Eli Lilly SPC judgments

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • January 22 2014

In addition to giving its decision in Georgetown University C-48412, the Court of Justice of the European Union (CJEU) handed down two other

Advocate General Jääskinen gives Georgetown University SPC opinion

  • McDermott Will & Emery
  • -
  • European Union, Netherlands, United Kingdom
  • -
  • December 16 2013

On 14 November 2013, Advocate General (AG) Jääskinen's opinion in the Dutch supplementary protection certificate (SPC) referral, Georgetown

European Commission fines pharmaceutical companies for Citalopram pay-for-delay agreements

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • June 30 2013

On 19 June 2013, the European Commission announced a fine of 93.8 million for H. Lundbeck AS (Lundbeck) and a further 52.2 million of fines levied

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • January 9 2013

In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge

EC introduces major changes to medical device regulation

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • December 17 2012

The European Commission has issued two proposals that, if approved, will fundamentally amend EU law on medical devices and in vitro diagnostics

What did you say? $31 million awarded for infringement of hearing aid patent

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

Increased European patent protection following a landmark ruling on supplementary protection certificates

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • August 30 2012

The Court of Justice of the European Union (CJEU) rendered judgment relating to a preliminary reference from the English Court of Appeal, holding that the existence of an earlier marketing authorization (MA) of a pharmaceutical product does not preclude the grant of a Supplementary Protection Certificate (SPC) for a different application of the same product

Advocate General opinion on the interpretation of “first marketing authorisation” for Supplementary Protection Certificates

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • June 7 2012

Advocate General Trstenjak (the AG) has rendered an opinion in a preliminary reference relating to Neurim Pharmaceuticals Ltd 1991 C-13011 that it should be possible to grant a Supplementary Protection Certificate (SPC) for a second medicinal product that comprises the same active ingredient as a medicinal product covered by a prior marketing authorisation (MA), if the scope of the basic patent protecting the second medicinal product does not extend to the earlier medicinal product